209 related articles for article (PubMed ID: 21986253)
1. Efficacy and safety of current drug therapies for invasive aspergillosis.
Traunmüller F; Popovic M; Konz KH; Smolle-Jüttner FM; Joukhadar C
Pharmacology; 2011; 88(3-4):213-24. PubMed ID: 21986253
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
3. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.
Kirkpatrick WR; Coco BJ; Patterson TF
Antimicrob Agents Chemother; 2006 Apr; 50(4):1567-9. PubMed ID: 16569887
[TBL] [Abstract][Full Text] [Related]
4. [Guideline based treatment of invasive aspergillosis].
Karthaus M
Mycoses; 2010 May; 53 Suppl 1():36-43. PubMed ID: 20433655
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
[TBL] [Abstract][Full Text] [Related]
6. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
8. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
11. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis.
Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II
Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093
[TBL] [Abstract][Full Text] [Related]
12. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.
Steinbach WJ; Stevens DA; Denning DW
Clin Infect Dis; 2003 Oct; 37 Suppl 3():S188-224. PubMed ID: 12975752
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine.
Krishnan-Natesan S; Chandrasekar PH; Manavathu EK; Revankar SG
Diagn Microbiol Infect Dis; 2008 Dec; 62(4):443-6. PubMed ID: 18842377
[TBL] [Abstract][Full Text] [Related]
14. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.
Kirkpatrick WR; Perea S; Coco BJ; Patterson TF
Antimicrob Agents Chemother; 2002 Aug; 46(8):2564-8. PubMed ID: 12121933
[TBL] [Abstract][Full Text] [Related]
17. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
Metcalf SC; Dockrell DH
J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
[TBL] [Abstract][Full Text] [Related]
18. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
Petrikkos GL
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin: new preparation. A last resort in invasive aspergillosis.
Prescrire Int; 2002 Oct; 11(61):142-3. PubMed ID: 12378745
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
